Episode Details

Novo Nordisk A/S (NVO) Q2 2026 — Q2 2026 (quarter ended June 30, 2026), reported in Danish kroner: adjusted net sales DKK 78,488M, +7% at constant currency. Adjusted operating profit DKK 33,389M, +11% CER. Adjusted diluted EPS per ADR DKK 6.18 against a bar worth about DKK 5.01 - a 23% beat. IFRS diluted EPS was DKK 4.75, DOWN 20%; the gap is DKK 6,328M of non-cash pipeline impairments. FY2026 guidance was RAISED from -4%/-12% to 0%/-6% CER. Novo published at 07.00 ET on Aug 4, before the US open: NVO opened $47.59, ran to $49.15, and closed $44.28 - down 5.97% on 47.5M shares against a 14.9M average. It closed Aug 7 at $46.90. Novo Nordisk beat the adjusted earnings bar by about 23% (DKK 6.18 vs roughly DKK 5.01), raised full-year guidance four points at both ends, and raised the free cash flow guide by DKK 9B - and the stock ran to $49.15 (+4.4%) then closed down 5.97% at $44.28 on triple volume. Four things nobody put on a slide. ONE: the raise is a raise of a DECLINE - guidance went from -4%/-12% to 0%/-6% CER, both ends still negative, and using Novo's own +5% CER non-adjusted midpoint the residual leaves H2 2026 at DKK 141,449M against H2 2025's DKK 153,922M, MINUS 8.1%. TWO: adjusted sales grew 6% in kroner and adjusted gross profit grew ZERO; margin went 82.7% to 78.2%, and the whole +11% CER profit growth came from cutting sales and distribution costs 13%. THREE: Wegovy pill is the best GLP-1 volume launch ever - 2.9M US scripts in the quarter - but DKK 3,218M over 2.9M scripts is about $170 a script, against a list price near $1,350 that halves to $675 on Jan 1, 2027. FOUR: H1 free cash flow was DKK 55.3B and the FULL-YEAR guide is DKK 45-55B, so the raised guide implies a second half between minus DKK 10B and roughly zero. We prove the EPS basis three ways. Fair value $38 vs $46.90 - and the Street's own MEDIAN target of $44.55 is already below the price. THE CALL: AVOID (4/5, A GREAT FRANCHISE, REPRICING ITSELF IN PUBLIC) — base-case value ~$38.0 vs ~$46.9 today. KEY METRICS: - CALL: AVOID 4/5, fair value ~$38 vs the $46.90 Aug 7 close (-19%). Bull $61, base $34, bear $21. Street: Buy, 14 analysts, avg target $47.12, MEDIAN $44.55. - Adjusted sales DKK 78,488M +7% CER. Adjusted EPS/ADR DKK 6.18 vs a ~DKK 5.01 bar (+23%). IFRS EPS DKK 4.75, -20%. Adjusted operating profit DKK 33,389M +11% CER. - But adjusted gross profit grew 0% and margin fell to 78.2% from 82.7%. The raised guide still implies H2 -8%. H1 FCF DKK 55.3B vs a DKK 45-55B full-year guide. What to watch: UP: Medicare Part D Bridge converting obesity into a reimbursed benefit at real prices; adjusted gross margin stabilising above 78%; Q3 landing at the top of the guide band; capex falling faster than the DKK 55B plan. DOWN: a Q3 sales decline confirming the implied -8% second half; the Jan 1 2027 US list-price cut to USD 675 landing without a volume offset; the flagged further ZEUS impairment; free cash flow confirming a second half near zero. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.